Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein like (BNIPL) is a protein encoded by the BNIPL gene in humans. BNIPL interacts physically with several other proteins, notably BCL2, ARHGAP1, MIF, and GFER, and may function as a bridge molecule between BCL2 (a key regulator of apoptosis) and ARHGAP1/CDC42 in promoting cell death[2][5]. The gene expresses multiple isoforms due to alternative splicing. BNIPL's interaction network suggests a role in regulating cellular apoptotic pathways, often implicated in the control of cell fate downstream of mitochondrial signaling. Dysregulation or altered expression of BNIPL has been associated with the development and progression of multiple types of cancer, including hepatocellular carcinoma and colorectal cancer, offering potential diagnostic and prognostic insights[4][5]. BNIPL is structurally related to members of the BCL2-interacting protein family, with key protein-protein binding properties, though it is not classified strictly as a receptor, enzyme, or transporter but rather as a scaffold/adaptor molecule within cell death regulatory networks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein like (BNIPL).